Seegnal and AARP Partner
Seegnal Joins AARP's AgeTech Accelerator to Expand Clinical Support in U.S. Healthcare
Seegnal Inc. (TSXV: SEGN) has been accepted into the Summer 2026 cohort of the AgeTech Collaborative™ from AARP Accelerator Program, the company announced on June 5, GlobeNewswire. The 8-week program connects health-tech startups with investors, enterprise partners, and hospital test sites focused on technology for adults 50 and older.
The acceptance is a major step in Seegnal's push into the United States, the world's largest healthcare market. The company's AI-powered clinical decision support platform is already used by more than 18,000 clinicians daily and has analyzed over 174 million prescriptions, according to Financial Post.
What the AARP Accelerator Gives Seegnal
The AgeTech Collaborative™ from AARP is run by the largest U.S. organization serving adults over 50. Its accelerator connects startups with a network of over 700 companies, including investors and "testbed" sites such as hospitals and retirement communities — all without taking equity, Ottawa Sun reported. Participants get strategic guidance and direct access to AARP's consumer insights.
CEO Elad Bibi-Aviv called it "an exciting step in our U.S. growth strategy," saying the program "connects us with a leading network in the U.S. AgeTech sector," GlobeNewswire reported. AARP's Andy Miller, Senior VP of Innovation, added that "the AgeTech Collaborative exists to ensure the most promising innovations reach the people who need them most."
The Drug Safety Problem Seegnal Is Built to Solve
Drug-related problems are the fourth leading cause of death in developed countries, killing roughly 150,000 Americans each year. Older adults face the highest risk because many take five or more medications at once — a condition called polypharmacy. Traditional safety alert systems have a 95% false-positive rate, which causes "alert fatigue": clinicians start ignoring the warnings entirely.
Seegnal's AI cuts through the noise. A 2021 study in Drug Safety found the platform produced 94% fewer alerts than legacy systems while still catching 69% more dangerous drug events that older tools missed. That clinical proof is central to Seegnal's pitch to U.S. health systems, The Sudbury Star noted.
A Fast-Moving U.S. Expansion Strategy in 2026
Seegnal has moved quickly this year. In March, its U.S. subsidiary signed a non-binding agreement with Mass General Brigham to test its tool in outpatient settings. In May, it signed a letter of intent with a U.S. long-term care provider for a pilot targeting elderly patients on multiple medications. Days before the AARP announcement, it raised $1.3 million CAD in a private placement to fund U.S. operations, Financial Post reported.
Analysts view long-term care facilities as a smart entry point. Because residents there manage multiple chronic conditions, the financial benefit of reducing hospitalizations can be shown quickly. The clinical decision support market is expected to grow from $4 billion in 2025 to $8.22 billion by 2034, a compound annual growth rate of 8.34%, according to industry data cited by Woodstock Sentinel Review.
Hurdles Ahead: Trust, Budgets, and Clinical Adoption
The road into U.S. clinics is not clear. A 2025 study found that 65.8% of U.S. adults have low trust in healthcare systems to use AI responsibly. Only 4.8% of patients said they do not need to be told when AI is used in their care. Seegnal will face strong demands for transparency as it enters American hospitals and nursing homes.
Practical barriers are also real. Research from the Journal of Medical Internet Research identified clinician adoption as the biggest obstacle, accounting for 33% of implementation problems. Long sales cycles and tight hospital budgets could slow revenue growth for the small-cap firm, which reported just US$1.26 million in revenue for fiscal year 2025, Montreal Gazette noted.
Sentiment
NeutralPublishers
9
Articles
9
Reach
9
